Oculis Acquires Global Rights to Privosegtor from Accure Therapeutics

Oculis Holding AG has signed an asset purchase agreement with Accure Therapeutics to acquire worldwide development and commercial rights to its lead neuroprotective candidate, Privosegtor (ACT-01), on August 10, 2026.

Under the terms, Oculis will pay $3.8 million (CHF 3.1 million) in cash upfront upon the first closing and may issue up to 2,050,000 Oculis ordinary shares, including milestone-based earnout shares, for both Privosegtor and the preclinical neurology candidate ACT-02.

The transaction will terminate Oculis’ existing license agreement with Accure, eliminating associated milestone payments and royalties, while strengthening Oculis’ control and economics over Privosegtor and consolidating its position in neuro-ophthalmology.

Privosegtor, a peptoid small molecule with potential as a first-in-class neuroprotective therapy, is being developed for optic neuropathies such as acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), and has received FDA Breakthrough Therapy and Orphan Drug designations.

The Privosegtor closing is expected by February 28, 2027, and the ACT-02 closing by March 31, 2027, subject to conditions precedent, with the ACT-02 closing dependent on completion of the Privosegtor transaction.